about
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coliRescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.Quiescent complement in nonhuman primates during E coli Shiga toxin-induced hemolytic uremic syndrome and thrombotic microangiopathy.Complement, thrombotic microangiopathy and disseminated intravascular coagulation.PROC, PROCR and PROS1 polymorphisms, plasma anticoagulant phenotypes, and risk of cardiovascular disease and mortality in older adults: the Cardiovascular Health Study.Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury.Sepsis and pathophysiology of anthrax in a nonhuman primate modelPro-Coagulant Endothelial Dysfunction Results from EHEC Shiga Toxins and Host Damage-Associated Molecular PatternsPlasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primatesThe pathogenesis of sepsis.The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex.A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity.Shiga Toxin Therapeutics: Beyond Neutralization.EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro.Plasma levels of endothelial protein C receptor respond to anticoagulant treatment.Microfluidic detection of movements of Escherichia coli for rapid antibiotic susceptibility testing.A computational solution to improve biomarker reproducibility during long-term projectsThe endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitorsThe endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptorThe effect of calcium ionophore A23187 on tissue factor activity and mRNA in endothelial cellsThe protein C pathway: new insightsBimodal distribution of soluble endothelial protein C receptor levels in healthy populationsPlasma levels of soluble endothelial cell protein C receptor in patients with Wegener's granulomatosisA phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group studySoluble thrombomodulin: a sign of bad times
P50
Q30442540-902C7860-209D-41B5-BAF5-A2A12F7B6076Q33388849-657CDA15-5FD2-43C8-A6B3-24B94B056B1FQ33395449-EBC6BA2E-7972-465C-A8D5-DCACD8A8343AQ33404640-7EAD6D71-AB62-454A-944E-0EDA0273BDD7Q33405827-CE56CCDF-6D25-4251-9F9A-1396199ABDCCQ33408183-336F2CFE-16C6-4B24-BF00-C2A0A9C2854EQ33420624-AC88DC66-1AB4-4548-844A-88579B2A0F09Q33798215-323B1285-FE81-4EDB-9CF6-376C050A6143Q35003696-9D7B4281-8B38-4B90-839A-1DBFA456568FQ35221982-B9FD7BC0-EA0F-47BB-80C5-B301B10F6BEFQ35295605-BC29C279-BB4C-4F46-87C8-5E8E37C24887Q36510003-424553CF-3B3D-497E-816C-48B6F2AA3C5DQ36934401-27BD4F77-7F28-4DA2-A44D-E89D34525EB1Q37331775-DE1D097B-AA70-4B64-8821-A52C862A7328Q38337766-C356C216-49B5-4A61-8A6B-393638BE24B0Q41669177-CF3A21DC-4BDA-4E2A-A793-DECD6BA79909Q42478892-2555DA56-3716-4205-BBE7-8CAB484B3526Q43847726-7369060F-6E5A-4561-B1E4-B714C061FF29Q48128325-6AD8F40C-6E45-4279-AADE-3D5FE42A042EQ64106506-ADC6061A-3A8C-4746-94C1-BEFFFB27FC72Q71144269-7602BEF9-72C0-4A65-B1AF-09E46A0B600FQ71144272-9CCF0C3B-9967-45B2-A2F8-747A1AC274BCQ72057104-C388A9E1-37EE-407A-A36E-451912FB2114Q73447280-FF7F6DDB-BA0A-4926-931A-634BF7191F19Q73690764-D66065EB-C8AB-43A3-BC82-90C47638FF8CQ74185352-D3A8BCAE-D6C3-45CE-BC13-3E244AEA539DQ80539568-07038328-D02D-4DAC-9959-AF8645DCB0E1Q81137878-99F518C6-F495-47C4-8862-DDC972351F68
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Deborah J Stearns-Kurosawa
@ast
Deborah J Stearns-Kurosawa
@en
Deborah J Stearns-Kurosawa
@es
Deborah J Stearns-Kurosawa
@nl
Deborah J Stearns-Kurosawa
@sl
type
label
Deborah J Stearns-Kurosawa
@ast
Deborah J Stearns-Kurosawa
@en
Deborah J Stearns-Kurosawa
@es
Deborah J Stearns-Kurosawa
@nl
Deborah J Stearns-Kurosawa
@sl
prefLabel
Deborah J Stearns-Kurosawa
@ast
Deborah J Stearns-Kurosawa
@en
Deborah J Stearns-Kurosawa
@es
Deborah J Stearns-Kurosawa
@nl
Deborah J Stearns-Kurosawa
@sl
P106
P21
P31
P496
0000-0003-2486-923X